Document Detail

Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
MedLine Citation:
PMID:  18524692     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes. METHODS: We prospectively studied 1131 consecutive patients without a history of liver disease seen for diabetes. The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy. RESULTS: The biomarker predicted advanced fibrosis in 63 of 1131 (5.6%) patients. A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma. In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696). CONCLUSIONS: The fibrosis biomarker might be used for the detection of advanced fibrosis in patients with type 2 diabetes.
Sophie Jacqueminet; Pascal Lebray; Rachel Morra; Mona Munteanu; Laure Devers; Djamila Messous; Maguy Bernard; Agnes Hartemann-Heurtier; Francoise Imbert-Bismut; Vlad Ratziu; Andre Grimaldi; Thierry Poynard
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-06-04
Journal Detail:
Title:  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association     Volume:  6     ISSN:  1542-7714     ISO Abbreviation:  Clin. Gastroenterol. Hepatol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-08     Completed Date:  2008-09-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160775     Medline TA:  Clin Gastroenterol Hepatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  828-31     Citation Subset:  IM    
Service de Diabétologie, APHP-GHPS, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers
Diabetes Complications*
Elasticity Imaging Techniques
Liver / pathology
Liver Cirrhosis / epidemiology*
Liver Function Tests / methods*
Mass Screening / methods*
Middle Aged
Prospective Studies
Severity of Illness Index
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinic...
Next Document:  P1 nuclease cleavage is dependent on length of the mismatches in DNA.